Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 31.50p 9,493 08:00:00
Bid Price Offer Price High Price Low Price Open Price
30.00p 33.00p 31.50p 31.50p 31.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.07 -16.91 -26.80 19.4

Diurnal (DNL) Latest News

More Diurnal News
Diurnal Takeover Rumours

Diurnal (DNL) Share Charts

1 Year Diurnal Chart

1 Year Diurnal Chart

1 Month Diurnal Chart

1 Month Diurnal Chart

Intraday Diurnal Chart

Intraday Diurnal Chart

Diurnal (DNL) Discussions and Chat

Diurnal Forums and Chat

Date Time Title Posts
20/5/201915:09Diurnal Group plc182

Add a New Thread

Diurnal (DNL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:15:3332.701,755573.89O
11:58:2330.107,6002,287.60O
09:05:5230.7513842.44O
View all Diurnal trades in real-time

Diurnal (DNL) Top Chat Posts

DateSubject
21/5/2019
09:20
Diurnal Daily Update: Diurnal Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DNL. The last closing price for Diurnal was 31.50p.
Diurnal Group Plc has a 4 week average price of 25p and a 12 week average price of 23.50p.
The 1 year high share price is 196p while the 1 year low share price is currently 21.50p.
There are currently 61,710,858 shares in issue and the average daily traded volume is 53,061 shares. The market capitalisation of Diurnal Group Plc is £19,438,920.27.
25/4/2019
08:52
costax1654x: From LSE: 225p Valuation!I must say this report sums up the situation very well, massive upside from here - 765% to be precise (225p target vs 26p current). https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf"Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL's first two products alone equates to £248m. Risk- adjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.""Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for a regulatory submission later this year. The share price also reflects the fact that the company will require more capital in 2019 in the absence of any significant licensing deals. DNL's US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator."
Diurnal share price data is direct from the London Stock Exchange
Your Recent History
LSE
DNL
Diurnal
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190521 18:32:58